August 14, 2026
Regenerative medicine of the cornea reached a turning point in 2026: at least 46 clinical trials are now exploring cell-based approaches to restore the ocular surface, most of them early-phase. Two recent advances illustrate complementary paths — cultivated limbal stem cells and biosynthetic implants — which intersect directly with the corneal healing mechanisms studied on this site.
A team at Mass Eye and Ear (Mass General Brigham) reported phase 1 results for cultivated autologous limbal epithelial cells (CALEC): stem cells taken from the patient's healthy eye are expanded in the laboratory, then transplanted onto the eye affected by limbal stem cell deficiency. In the 14 patients followed for 18 months, complete or partial restoration of the corneal surface was achieved in over 90% of cases, without further harvesting from the healthy contralateral eye beyond an initial small biopsy.
In parallel, a trial conducted in Sweden tested biosynthetic corneal implants (recombinant collagen) in ten patients with scarring or advanced keratoconus, with reported improvement in transparency and visual function, without the need for donor tissue. This approach is part of a broader trend toward tissue substitutes aimed at addressing the global shortage of donor corneas.
These results remain early-phase data, from small cohorts, with efficacy that varies by pathology type, disease stage and patient background. As of today they do not change the standard management of corneal ulceration and delayed healing, which relies on current treatments detailed in the corneal healing course and the review of therapeutic agents on this site — particularly the role of macrophages and epithelial-stromal interactions (EMMPRIN/CD147) in steering healing toward fibrosis or stromal melting. They do, however, point to the direction that management of severe limbal stem cell deficiency and non-graftable corneas is likely to take in the coming years.
This article summarizes external scientific publications and press releases, unrelated to trials conducted by Pr Gabison. It aims to place these advances in perspective with the corneal wound-healing physiopathology taught on this site — and with our own work on the corneal stem-cell niche: a study published in Acta Biomaterialia on 3D-printed hydrogels recreating this niche, the preliminary work that secured the national PEPR Biotherapies "COBRAS" grant (France 2030), in partnership with AP-HM and Rouen University Hospital.
Healthcare professional? The corneal macrophages course and the epithelial-stromal interactions course detail the biological mechanisms discussed here. Patient version: corneal healing information sheet.
← Back to home